News
09.12.2019 | Press Release
New preclinical study shows antibody therapy could offer treatment path for genetic form of ALS22.10.2019 | Press Release
Neurimmune Welcomes Biogen's News on Clinical Benefit of Aducanumab21.03.2019 | Company News
Biogen and Eisai to discontinue Phase 3 ENGAGE and EMERGE trials of Aducanumab05.03.2019 | Company News
Neurimmune-led research consortium receives Target ALS discovery grant04.03.2019 | Press Release
NovaGo Therapeutics raises CHF 10 million to develop regenerative anti-Nogo therapy for stroke01.03.2019 | Press Release
Neurimmune appoints John Dellapa as General Counsel01.11.2018 | Company News
Neurimmune appoints Natascha Schill as VP Project & Alliance Management18.09.2018 | Press Release
Neurimmune Achieves Milestone in Collaboration with Ono Pharmaceutical12.09.2018 | Company News
Neurimmune appoints Christoph Hock as Chief Medical Officer to lead clinical development